Niveles séricos de interleucina-6 en pacientes con diabetes tipo 2 y su correlación con el perfil lipídico

Jorge Escalera; Lorena Pérez; Sara Brito; Mary Lares; Luis Flores; Jorge Castro

Authors

Jorge Escalera
Lorena Pérez
Sara Brito
Mary Lares
Luis Flores
Jorge Castro

Keywords:

interleucine-6, lipid profile, type 2 diabetes mellitus.

Abstract

Diabetes mellitus is a metabolic disease characterized by hyperglycemia, because of defects in the production, secretion and / or action of insulin, producing alterations in the metabolism of carbohydrates, lipids and proteins; associated with a process of chronic inflation in a variable period, it will cause macro and microvascular lesions. Objective: Evaluate serum levels of interleukin-6 (IL-6) in type 2 diabetic patients and their correlation with lipid profile. Methods: An analytical and cross-sectional descriptive study was carried out, including 60 adults of both sexes between the age of 30 and 60, with type 2 diabetes mellitus who attended the Endocrinology consultation of the Hospital Militar Universitario Dr. Carlos Arvelo. Basal blood glucose, interleucine-6, lipid profile, and anthropometric parameters, body composition, age, and time of evolution of diabetes, was determined. Results: The average age of 51.60 years ± 6.51, where 71.6% corresponded to the female sex and 28.3% to the male, diabetes evolution time between a month and 37 years, with an average of 10.97 years. A statistically significant low positive correlation between interleukin-6 and triglyceride, VLDL and non-HDL parameters was presented. Conclusion: Elevated IL-6 values were found in all type 2 diabetic patients, as well as a positive correlation between IL-6 and triglyceride-rich lipoproteins. This supports the idea that hypertriglyceridemia can cause inflammatory changes in diabetic patients and this would raise the cardiovascular risk of these patients.

Downloads

Download data is not yet available.

References

Nieto R, Marulanda M, González J, Ugel E, Durán M. Estudio Venezolano de salud cardiometabólica Evescan. Rev. Sociedad Venezolana de Medicina Interna. 2017.

Le Roit D, Taylor SI, Olefssky JM. Diabetes Mellitus. Texto básico y clínico. 2ª ed. Ed. Mc-Graw Hill, Interamericana. México, D.F.2003; 1331.

Secretaría de Salud Modificación a la Norma Oficial Mexica-na, NOM-015-SSA2- 1994, para la prevención, tratamiento y control de la diabetes mellitus en la atención primaria. México D.F.: Diario Oficial de la Federación, 7 de abril 2000.

Crook MA, Tutt P, Pickup JC. Concentración sérica elevada de ácido siálico en la DMNID y su relación con la presión arterial y la retinopatía. Cuidado de la diabetes. 1993; 16 (1): 57-60.

Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM como una enfermedad del sistema inmunitario innato: asociación de reactantes de fase aguda e interleucina-6 con síndrome metabólico-X. Diabetologia. 1997; 40 (11): 1286-92.

Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. Proteína C reactiva, interleucina 6 y riesgo de desarrollar diabetes mellitus tipo 2. Jama 2001; 286 (3): 327-34.

Meigs JB, Hu FB, Rifai N, Manson JE. Biomarcadores de disfunción endotelial y riesgo de diabetes mellitus tipo 2. Jama 2014; 291 (16): 1978-86.

Gabay C. Interleucina-6 y la inflamación crónica. Artritis de Investigación y Terapia. 2006; 8 (Suppl 2): 3.

Dinarello, AC. 2000. Proinflammatory cytokines. Chest; 118: 503-508.

Akira S, Taga T, Kishimoto T: Interleukin-6 in biology and medicine. Adv Immunol. 1993; 54: 1-78.

Pedersen BK, Steensberg A, Fischer C, Keller C, Keller P, Plomgaard P, Febbraio M, Saltin B: Searching for the exercise factor: is IL-6 a candidate? J Muscle Res Cell Motil. 2003; 24: 113-119.

Beisswenger P.I., Drummond K.S., Nelson R.G., Howell S.K., Szwergold B.S., Mauer M. Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes.2005; 54:3274-81.

Moreira E.D., Neves R.C., Nunes Z.O., de Almeida M.C., Mendes A.B., Fittipaldi J.A. Glycemic control and its correlates in patients with diabetes in Venezuela: results from a nationwide survey. Diabetes Res Clin Pract.2010;87:407-14.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35:1364-79.

Mohamed Abdelrahman. Evaluación de la interleucina 6, la proteína C reactiva de alta sensibilidad y los niveles de perfil de lípidos en sudaneses con diabetes mellitus tipo 2. 5 ª Conferencia Internacional de Química Médica y asistido por ordenador de Drogas El diseño y la administración de fármacos December 05-07, 2016 Phoenix, USA.

Fontana Rodrigues. Niveles / polimorfismos de IL-6, TNF-α e IL-10 y su asociación con diabetes mellitus tipo 2 y obesidad en individuos brasileños. Arco. Endocrinol Metab. 2017; 61 (5).

Barter PJ, Ballantyne CM, Carmena R, Castro-Cabezas M, Chapman MJ, Couture P. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Medicine 2006; 259: 247–258.

Wagner AM, Perez A, Calvo F, Bonet R, Castellvi A, Ordonez J: Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients. Diabetes Care 1999; 22(5):812-817.

Wagner AM, Perez A: [Diabetic dyslipidemia: assessment and treatment]. Med Clin (Barc ) 2002; 119(7):260-264.

Mooradian AD: Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009; 5(3):150-159.

Krauss RM: Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004; 27(6):1496-1504.

Ginsberg HN: Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106(4):453-458.

Beers A, Haas MJ, Wong NC, Mooradian AD: Inhibition of apolipoprotein AI gene expression by tumor necrosis factor alpha: roles for MEK/ERK and JNK signaling. Biochemistry 2006; 45(7):2408-2413.

Castro J, Lares M, Obregón O. El Colesterol no HDL como marcador de riesgo cardiovascular 2004; 29 (1/2): 3-6

Paul M. Ridker, Jean G: MacFadyen, Robert J. Glynn, Gary Bradwin, Ahmed A. Hasan, and Nader Rifai Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. European Heart Journal 2020; 41, 2952-2961.

Sindhu S, Thomas R, Shihab P, Sriraman D, Behbehani K, Ahmad R. 2015. Obesity is a Positive Modulator of IL-6R and IL-6 Expression in the Subcutaneous AdiposeTissue: Significance for Metabolic Inflammation. PLoS One 2015; 10 (7): e0133494.

Dominique Hansen, Paul Dendale, Milou Beelen, Richard AM Jonkers, Annelies Mullens, Luk Corluy, Romain Meeusen, yLuc JC van Loon, Plasma Adipokine and inflammatory marker concentrations are altered in obese as opposed to non-obese, type 2 diabetes patients European Journal of Applied Physiology 2010, 109,379-404.

Goyal R, Faizy AF, Siddiqui SS, Singhai M. Evaluation of TNF-α aand IL-6 in obese and non-obese Diabetics: Pre – and postinsulin effects. N Am J Med Sci 2012; 4: 180-4.

Obregon O, Aure G, Disfunción mitocondrial y mecanismos fisiopatológicos relacionados con la dislipidemia del síndrome plurimetabolico, Aterosclerosis al día VII. Publicación de la asociación de la sociedad venezolana de ateroesclerosis, caracas: ediciones AVA; 2009 p;170-181.

Marsh JB: Lipoprotein metabolism in obesity and diabetes: insights from stable isotope kinetic studies in humans. Nutr Rev 2003; 61(11):363-375.

Austin MA, King MC, Vranizan KM, Krauss RM: Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82(2):495-506.

Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115:450-8.

Ponte C, Isea-P J. Machado L, Sánchez O, Melendéz R, Feijo J. The 2009 World Congress of Cardiology Abstracs. Buenos Aires, Argentina, May 18-21, 2009: poster presentations circulation.

Kaneto H, Katakami N, Matsuhisa M, Matsuoka TA (2010) Role of Reactive Oxygen Species in the Progression of Type 2 Diabetes and Atherosclerosis. Mediators Inflamm 2010: Article ID 453892,1 pages, doi:10.1155/2010/453892.

Likidlilid A, Patchanans N, Peerapatdit T, Sriratanasathavorn C. (2010) Lipid peroxidation and antioxidant enzyme activities in erythrocytes of type 2 diabetic patients. J Med Assoc Thai 93(6):682-693.

Takayanagi R, Inoguchi T, Ohnaka K (2011) Clinical and experimental evidence for oxidative stress as an exacerbating factor of diabetes mellitus. J Clin Biochem Nutr 48 (1): 72-77.